CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	11.09	-0.57	-99.32	-115.87	-64.82	-132.83
Depreciation & Amortization	1.9	2.18	2.44	2.71	2.57	2.61
Asset Writedown & Restructuring Costs	-	-	0.25	-	-	-
Loss (Gain) From Sale of Investments	-7.46	-7.42	-0.05	0.27	-0.24	-2.23
Stock-Based Compensation	7.57	8.56	13.13	13.17	14.79	19.1
Other Operating Activities	3.9	3.73	3.41	3.13	2.89	4.27
Change in Accounts Receivable	-0.87	32.55	-35.2	0.01	-0.79	0.08
Change in Accounts Payable	-0.5	-1.43	0.07	-0.14	-0.86	-0.37
Change in Unearned Revenue	-100.68	-89.01	16.57	-33.95	62.83	-17.15
Change in Other Net Operating Assets	-0.74	-4.63	-12.09	11.64	-11.12	-13.96
Operating Cash Flow	-85.8	-56.04	-110.79	-119.03	5.26	-140.48
Capital Expenditures	-0.49	-0.84	-1.74	-1.61	-2.31	-3.5
Investment in Securities	36.81	-149.83	100	24.1	-16.41	83.2
Investing Cash Flow	36.33	-150.67	98.26	22.49	-18.72	79.7
Issuance of Common Stock	5.52	0.56	0.65	110.21	16.89	1.63
Other Financing Activities	29.67	29.67	-	-	-	-
Financing Cash Flow	35.19	30.23	0.65	110.21	16.89	1.63
Net Cash Flow	-14.29	-176.48	-11.88	13.67	3.43	-59.15
Free Cash Flow	-86.29	-56.88	-112.53	-120.64	2.95	-143.98
Free Cash Flow Margin	-72.16%	-56.19%	-211.67%	-323.33%	4.31%	-535.19%
Free Cash Flow Per Share	-1.04	-0.77	-1.71	-1.88	0.06	-3.18
Cash Income Tax Paid	-	-	-	-	-	13.06
Levered Free Cash Flow	14.55	43.66	-8.92	-46.11	-53.86	-83.19
Unlevered Free Cash Flow	14.55	43.66	-8.92	-46.11	-53.86	-83.19
Change in Net Working Capital	-2	-37.82	-35.9	-12.16	18.57	12.97

Source: S&P Capital IQ. Standard template. Financial Sources.